

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5936512

|   |                                 |
|---|---------------------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                  |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                      |
| <b>SEQUENCE:</b>  | 5                               |
| <b>CONVEYING PARTY DATA</b>   |                                 |
| <b>Name</b>   | <b>Execution Date</b>           |
| JANSSEN PHARMACEUTICA NV  | 04/27/2016                      |
| <b>RECEIVING PARTY DATA</b>   |                                 |
| <b>Name:</b>  | JANSSEN SCIENCES IRELAND UC     |
| <b>Street Address:</b>  | EASTGATE VILLAGE                |
| <b>Internal Address:</b>  | EASTGATE, LITTLE ISLAND         |
| <b>City:</b>  | CO CORK                         |
| <b>State/Country:</b>   | IRELAND                         |
| <b>PROPERTY NUMBERS Total: 1</b>  |                                 |
| <b>Property Type</b>  | <b>Number</b>                   |
| <b>Application Number:</b>  | 16272934                        |
| <b>CORRESPONDENCE DATA</b>  |                                 |
| <b>Fax Number:</b>  | (650)583-2042                   |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                                 |
| <b>Phone:</b>   | 6507635604                      |
| <b>Email:</b>   | crubalca@its.jnj.com            |
| <b>Correspondent Name:</b>  | JOSEPH F. SHIRTZ                |
| <b>Address Line 1:</b>  | JOHNSON & JOHNSON               |
| <b>Address Line 2:</b>  | ONE JOHNSON & JOHNSON PLAZA     |
| <b>Address Line 4:</b>  | NEW BRUNSWICK, NEW JERSEY 08933 |
| <b>ATTORNEY DOCKET NUMBER:</b>  | TIP0330USCNT1                   |
| <b>NAME OF SUBMITTER:</b>   | CANDIDA RUBALCABA-RIVERA        |
| <b>SIGNATURE:</b>   | /CANDIDA RUBALCABA-RIVERA/      |
| <b>DATE SIGNED:</b>   | 01/29/2020                      |
| <b>Total Attachments: 1</b>   |                                 |
| source=TIP0330USPCT Janssen NV to Janssen UC#page1.tif  |                                 |

## General Assignment

WHEREAS, JANSSEN PHARMACEUTICA NV, having its place of business at Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

## "RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS"

for which on 27<sup>th</sup> day of April 2016, International Patent Application no. PCT/EP2016/059392 was filed at the European Patent Office.

WHEREAS, Janssen Sciences Ireland UC, having its place of business at Eastgate Village, Eastgate, Little Island, Co Cork, Ireland (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 27<sup>th</sup> day of April 2016.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen Pharmaceutica NV



.....  
Luc Quaghebeur, Authorized Signatory  
For Janssen Pharmaceutica NV

For Janssen Sciences Ireland UC



.....  
Frank Daelemans, Authorized Signatory  
For Janssen Sciences Ireland UC